The Ministry of Health and Prevention represented for the UAE at the Third Arab Conference for Food, Medicines and Medical Devices kept in Egypt under the theme 'The Future Begins Today.' Among the event's guests are H.E. Dr. Ahmed Radi, Egyptian Minister of Health and Populace; H.E. Dr Ali Hyasat, previous Jordanian Minister of Health, H.E. Dr. Hamad Al Manea, Saudi Minister of Health; Dr. Hisham bin Sa'ad Al-Judaei, Chief Executive Officer of Saudi Food & Drugs Authority (SFDA); H.E. Dr. Nasser AlQahtani, Director General of the Arab Administrative Development Organization (ARADO); H.E. Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Health Policy and Licensing at the UAE Ministry of Health and Prevention and Chairman for Supreme National Pharmacovigilance Committee; along with ministers, undersecretaries and agents from Arab and worldwide pharmaceutical firms and the Arab Institute for Training and Study of the League of Arab States. Around 700 participants participated in the event.

H.E. Dr. Al Amiri kept in mind that the leading forum gathered choice manufacturers in government and exclusive Arab and international entities, scientists, and academic researchers from prominent universities. The UAE chaired the second session covering the intergovernmental discussion kept in the existence of local, regional, and global medication producers and government choice manufacturers. The UAE, an exemplary version in the Arab world's medication and health market, supplied a lecture throughout the meeting.

UAE at forefront of building world-class health care sector

In his lecture, Dr. Al Amiri said that the UAE goes to the forefront of developing a best-in-class healthcare industry in the region backed by strong government assistance, durable enablers and National Agenda that shaped all national approaches; UAE Vision 2021; Smart Government Campaign; the National Innovation Technique, Foresing the Future 2050, and the UAE Centennial 2071.

He included that the expected growth of the pharmaceutical market in the UAE is anticipated to increase from AED 11.3 billion this year to AED 20.6 billion in 2027 at a general price of 82.3 percent. The market share of the personal health care industry, in particular, has experienced considerable increase over the previous few years and is anticipated to expand more to get to over AED 30 billion backed up by the assistance and assistance of an accountable public market.

The variety of drug manufacturers operating in the UAE is expected to strike 36 by 2020 from the present 18, while the number of clinical workplaces, which is presently at 47, is predicted to climb to 75 by 2020. The projected growth is based upon the Ministry's efforts to encourage investment in the pharmaceutical market in the visibility of a modern facilities, airports, and complimentary areas.

Challenges facing Arab pharmaceutical industry

Inning Accordance With H.E. Dr. Al Amiri, the UAE has submitted an incorporated record on one of the most pressing challenges encountering the pharmaceutical and clinical gadget industries in Arab nations after conducting a study. The nation likewise submitted a different report on key referrals to difficulty these difficulties which include absence of an unified platform for pharmaceutical item enrollment and absence of a merged Arab medication market in addition to the absence of an Arab board for drug registration just like the GCC Central Committee for Drug Enrollment. Other problems elevated are different local medicine enrollment treatments; lack of details exchange in between pertinent authorities; postponed release of drug shipments in ports; import and re-export issues; and the requirement for a specialized Arab body to discuss and address obstacles and challenges in this area.

Pharmacovigilance system

H.E. Dr. Al Almiri additionally explained that pharmacovigilance continues to be a tough point for all Arab countries due to absence of information exchange and inadequate communication, specifically relating to the innovative medicine system; absence of post-marketing surveillance prior to withrawal of medicines; non-disclosure of marketing details; weak guidelines regulating private business such as enforcing fines on pharmaceutical companies by the Fda; lack of comments amongst Arab nations on all areas of the drug industry; non-compliance of some Arab nations with intellectual property rights; and lack of pharmaceutical research and development facilities that can generate Arab innovative medicine that we could be pleased with.

UAE recommendations during meeting of Council of Arab Ministers of Health

H.E. Dr. Al Amiri additionally shared the UAE's recommendations to attend to the have to improve the technological and scientific collaboration between Arab countries and regional and worldwide medication organizations. The recommendations likewise aim to strengthen industry cooperation amongst Arab countries; establish a monitoring system to review and apply amendments; and develop signs to assess and determine efficiency of pertinent policies after the suggested application period. HE additionally highlighted the need to establish state-of-the-art manufacturing facilities and pharmaceutical research centers to promote innovation, encourage study, and keep pace with the evolving global industry.

Furthermore, H.E. discussed the need to formulate key medication regulations in the Arab world. The regulations need to concentrate on establishing specific mechanisms to safeguard Arab manufacturers; developing entities in charge of researching the pharmaceutical market and intending its growth, and efficient pharmaceutical plans; sharing GMP records amongst nations; and supplying a linked reference for pharmaceutical item enrollment and conformity with all TRIPS clauses.

Various other recommendations consisted of supporting the Arab pharmaceutical companies to enhance their competitiveness; boosting the innovative pharmacovigilance system; promoting the Arab markets abroad; and forming an Arab body to review barriers and challenges in the medication industry. The referrals were submitted to the Council of Arab Ministers of Health for approval and adoption in their following meeting.

Quality of pharmaceutical systems and importance of governance

The conference highlighted the need to develop governing and tracking procedures in the Arab nations as per the standards in connection with quality systems for food, medications, medical tools, and products. The occasion also focused on the value of governance and legal and governing structures in making sure the safety of food, drugs and medical tools, while supporting the localization of food, drugs and medical tools in addition to protecting Arab customers through regulations and regulative systems to ensure safe food and medicine.